What Is Synthetic Lethality? How PARP Inhibitors Work in Cancer Treatment

Learn how synthetic lethality works in cancer treatment and how PARP inhibitors target tumors with BRCA1/2 alterations or homologous recombination deficiency.

Top Stories

Global Accessibility of Spinal Muscular Atrophy (SMA) Treatment: Current Status Analysis

A New Option in Targeted Biologic Therapy: Clinical Insights into Guselkumab Injection

Latest Coverage

Chinese HER2 Bispecific Antibody + PD-1 Combination Approved in the U.S. for Gastroesophageal Adenocarcinoma, Advancing to the Forefront of Global Oncology
For patients with advanced gastroesophageal adenocarcinoma (GEA), treatment is entering a new phase.

Bone Marrow Protection Throughout Chemotherapy: Trilaciclib Approved for a New Indication, Extending from First-Line to Post-Relapse Treatment
For patients with extensive-stage small cell lung cancer (ES-SCLC), treatment challenges extend beyond the cancer its...

The 30-Year Chemotherapy Standard Faces a New Challenge: China's PD-1 Serplulimab Breaks New Ground in Gastric Cancer Treatment
The 30-Year Chemotherapy Standard Faces a New Challenge: China’s PD-1 Serplulimab Breaks New Ground in Gastric Cancer...

Breaking Through for an Asian Cancer: China’s Innovation Rewrites the Future of Nasopharyngeal Cancer Treatment
What happens when a patient with nasopharyngeal cancer sees the disease progress again after first- and second-line t...

Sevabertinib for HER2-Mutant NSCLC in China: A New Targeted Treatment Option
From EGFR and ALK to ROS1, RET, MET, and HER2, advances in genetic testing and targeted therapies are enabling more p...

Current Status of Immunotherapy for Bladder Cancer: From BCG to Precision Combination Therapy
Bladder cancer is one of the most common malignancies of the urinary system. A substantial proportion of patients are...

In-Depth Analysis

What Is Synthetic Lethality? How PARP Inhibitors Work in Cancer Treatment

Global Accessibility of Spinal Muscular Atrophy (SMA) Treatment: Current Status Analysis

A New Option in Targeted Biologic Therapy: Clinical Insights into Guselkumab Injection

Chinese HER2 Bispecific Antibody + PD-1 Combination Approved in the U.S. for Gastroesophageal Adenocarcinoma, Advancing to the Forefront of Global Oncology